Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy.
Cristina Marisol Castillo BautistaKristin EismannMarc GentzelSilvia PelucchiJerome MertensHannah E WaltersMaximina Hee YunJared SterneckertPublished in: Cells (2023)
Aging is associated with the disruption of protein homeostasis and causally contributes to multiple diseases, including amyotrophic lateral sclerosis (ALS). One strategy for restoring protein homeostasis and protecting neurons against age-dependent diseases such as ALS is to de-repress autophagy. BECN1 is a master regulator of autophagy; however, is repressed by BCL2 via a BH3 domain-mediated interaction. We used an induced pluripotent stem cell model of ALS caused by mutant FUS to identify a small molecule BH3 mimetic that disrupts the BECN1-BCL2 interaction. We identified obatoclax as a brain-penetrant drug candidate that rescued neurons at nanomolar concentrations by reducing cytoplasmic FUS levels, restoring protein homeostasis, and reducing degeneration. Proteomics data suggest that obatoclax protects neurons via multiple mechanisms. Thus, obatoclax is a candidate for repurposing as a possible ALS therapeutic and, potentially, for other age-associated disorders linked to defects in protein homeostasis.
Keyphrases
- amyotrophic lateral sclerosis
- small molecule
- protein protein
- spinal cord
- stem cells
- cell death
- endoplasmic reticulum stress
- oxidative stress
- signaling pathway
- amino acid
- binding protein
- emergency department
- transcription factor
- mouse model
- spinal cord injury
- resting state
- brain injury
- mesenchymal stem cells
- deep learning
- functional connectivity
- high glucose
- adverse drug
- subarachnoid hemorrhage